See more : Benchmark Holdings plc (BMK.L) Income Statement Analysis – Financial Results
Complete financial analysis of Medeon Biodesign, Inc. (6499.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medeon Biodesign, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Altimar Acquisition Corp. II (ATMR) Income Statement Analysis – Financial Results
- Kinnevik AB (KINV-B.ST) Income Statement Analysis – Financial Results
- Chukai Public Company Limited (CRANE.BK) Income Statement Analysis – Financial Results
- Calyxt, Inc. (CLXT) Income Statement Analysis – Financial Results
- Halozyme Therapeutics, Inc. (0J2O.L) Income Statement Analysis – Financial Results
Medeon Biodesign, Inc. (6499.TWO)
About Medeon Biodesign, Inc.
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in Taiwan and the United States. The company focuses on developing devices for minimally invasive surgeries, such as Duett, a vascular graft system; ClickClean, a solution to view throughout laparoscopic surgeries; AbClose to prevent port site herniation caused by improper closure; UroCross, an expander system; PUMA, a solution to treat orthopedic extremity injuries; and Cross-Seal, a large-bore closure device. It is involved in medical device contract manufacturing, equity investment and commerce of medical devices, manufacturing and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is headquartered in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 196.26M | 298.32M | 68.96M | 123.06M | 453.76M |
| Cost of Revenue | 261.46M | 111.51M | 40.33M | 76.75M | 267.52M |
| Gross Profit | -65.20M | 186.81M | 28.63M | 46.30M | 186.24M |
| Gross Profit Ratio | -33.22% | 62.62% | 41.52% | 37.63% | 41.04% |
| Research & Development | 663.92M | 521.62M | 415.87M | 289.94M | 300.95M |
| General & Administrative | 0.00 | 127.74M | 65.90M | 39.52M | 59.81M |
| Selling & Marketing | 0.00 | 25.28M | 42.45M | 58.98M | 82.19M |
| SG&A | 110.45M | 153.03M | 108.35M | 98.50M | 141.99M |
| Other Expenses | 0.00 | -4.04M | -43.07M | -8.59M | -11.68M |
| Operating Expenses | 774.37M | 674.65M | 524.22M | 388.44M | 442.94M |
| Cost & Expenses | 1.04B | 786.15M | 564.55M | 465.20M | 710.46M |
| Interest Income | 19.94M | 10.29M | 6.12M | 9.61M | 17.64M |
| Interest Expense | 6.64M | 5.21M | 1.03M | 1.39M | 2.74M |
| Depreciation & Amortization | 95.67M | 63.80M | 59.02M | 84.27M | 79.25M |
| EBITDA | -1.14B | -370.10M | -453.87M | -256.46M | -172.08M |
| EBITDA Ratio | -581.83% | -124.06% | -658.19% | -208.73% | -37.79% |
| Operating Income | -839.57M | -433.90M | -512.88M | -341.12M | -250.74M |
| Operating Income Ratio | -427.78% | -145.45% | -743.77% | -277.21% | -55.26% |
| Total Other Income/Expenses | -404.67M | -52.90M | -20.69M | -992.00K | -3.33M |
| Income Before Tax | -1.24B | -439.12M | -513.91M | -342.12M | -254.07M |
| Income Before Tax Ratio | -633.96% | -147.20% | -745.26% | -278.02% | -55.99% |
| Income Tax Expense | 39.29M | 57.79M | 72.46M | 5.28M | 28.65M |
| Net Income | -1.20B | -433.76M | 2.08B | -192.74M | -261.99M |
| Net Income Ratio | -613.78% | -145.40% | 3,013.75% | -156.62% | -57.74% |
| EPS | -13.09 | -4.71 | 22.65 | -2.10 | -2.86 |
| EPS Diluted | -13.09 | -4.71 | 22.57 | -2.10 | -2.86 |
| Weighted Avg Shares Out | 92.04M | 92.02M | 91.75M | 91.64M | 91.59M |
| Weighted Avg Shares Out (Dil) | 92.04M | 92.02M | 92.08M | 91.64M | 91.59M |
Source: https://incomestatements.info
Category: Stock Reports